In 2011,, Boehringer Ingelheim made more than $350 million in capital investments throughout its U.S. operations expanding drug discovery, development and manufacturing capabilities.
The company’s latest investment is a 72,000 square-foot research and development facility at the company’s U.S. headquarters in Ridgefield, Conn. When complete, the $65 million facility will handle production of active pharmaceutical ingredients used in early development activities. Approved products developed at the headquarters will move on to the company’s facilities in Ohio, Virginia, Germany, and Italy.
In August, the company announced an investment in a drug safety assessment building at the Ridgefield location. The $42 million project is scheduled to be completed in 2013 and will provide space for non-clinical safety studies.
This summer, the company’s U.S. animal health business, Boehringer Ingelheim Vetmedica Inc. dedicated a $89 million vaccine research facility in Sioux Center, Iowa, as one of three vaccine research buildings to be built there. The company also announced a $100 million expansion of its biological manufacturing facility in St. Joseph, Miss.
In September, Boehringer Ingelheim Roxane, Inc. opened a $50 million high containment operations facility in Columbus, Ohio to meet a growing market demand for high potency and oncology products. In March, the company acquired a 300,000 square feet facility from Amgen to manufacture biological medicines for clinical and market supplies.
Release Date: Nov. 15, 2011
Source: Boehringer Ingelheim
